Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dentistry
Volume 2013, Article ID 542130, 5 pages
http://dx.doi.org/10.1155/2013/542130
Case Report

Neuroleptic Malignant Syndrome in a Patient with Tongue Cancer: A Report of a Rare Case

1Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Ibaraki, Tsukuba City 305-8575, Japan
2Department of Clinical Pathophysiology of the Neurological Disorders, Faculty of Medicine, University of Tsukuba, Japan

Received 26 April 2013; Accepted 26 May 2013

Academic Editors: C. Landes and A. Milosevic

Copyright © 2013 Osamu Baba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. N. Caroff, “The neuroleptic malignant syndrome,” Journal of Clinical Psychiatry, vol. 41, no. 3, pp. 79–83, 1980. View at Google Scholar · View at Scopus
  2. P. Adnet, P. Lestavel, and R. Krivosic-Horber, “Neuroleptic malignant syndrome,” British Journal of Anaesthesia, vol. 85, no. 1, pp. 129–135, 2000. View at Google Scholar · View at Scopus
  3. S. Stübner, E. Rustenbeck, R. Grohmann et al., “Severe and uncommon involuntary movement disorders due to psychotropic drugs,” Pharmacopsychiatry, vol. 37, supplement 1, pp. S54–S64, 2004. View at Google Scholar · View at Scopus
  4. J. R. Strawn, P. E. Keck Jr., and S. N. Caroff, “Neuroleptic malignant syndrome,” The American Journal of Psychiatry, vol. 164, no. 6, pp. 870–876, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Tanaka, T. Akechi, M. Yamazaki, R. Hayashi, Y. Nishiwaki, and Y. Uchitomi, “Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient: a case report,” Support Care Cancer, vol. 6, no. 6, pp. 536–538, 1998. View at Google Scholar
  6. Y. Zohar, Y. P. Talmi, R. Sabo, Y. Finkelstein, and A. Korzets, “Neuroleptic malignant syndrome during perphenazine treatment in a patient with head and neck cancer: a case report,” Otolaryngology, vol. 106, no. 2, pp. 206–208, 1992. View at Google Scholar
  7. A. P. Association, “Diagnostic and statistical manual of mental disorders: DSM-IV,” in Neuroleptic Malignant Syndrome, The American Psychiatric Association, Washington, DC, USA, 4th edition, 1994. View at Google Scholar
  8. K. Nishijima, Neuroleptic Malignant Syndrome and Related Disoders, 1st edition, 2010.
  9. B. H. Guze and L. R. Baxter Jr., “Neuroleptic malignant syndrome,” The New England Journal of Medicine, vol. 313, no. 3, pp. 163–166, 1985. View at Publisher · View at Google Scholar
  10. S. N. Caroff and S. C. Mann, “Neuroleptic malignant syndrome,” Medical Clinics of North America, vol. 77, no. 1, pp. 185–202, 1993. View at Google Scholar
  11. K. Otani, M. Horiuchi, T. Kondo, S. Kaneko, and Y. Fukushima, “Is the predisposition to neuroleptic malignant syndrome genetically transmitted?” British Journal of Psychiatry, vol. 158, pp. 850–853, 1991. View at Google Scholar · View at Scopus
  12. K. Mihara, T. Kondo, A. Suzuki et al., “Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome,” The American Journal of Medical Genetics, vol. 117, no. 1, pp. 57–60, 2003. View at Google Scholar · View at Scopus
  13. R. D. Myers, “Neurochemistry of thermoregulation: two negatives make a positive,” Brain Research Bulletin, vol. 50, no. 5-6, pp. 453–454, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. G. J. Chandran, J. R. Mikler, and D. L. Keegan, “Neuroleptic malignant syndrome: case report and discussion,” CMAJ, vol. 169, no. 5, pp. 439–442, 2003. View at Google Scholar · View at Scopus
  15. G. Tollefson, “A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia,” Journal of Clinical Psychopharmacology, vol. 2, no. 4, pp. 266–270, 1982. View at Google Scholar · View at Scopus
  16. J. L. Levenson, “Neuroleptic malignant syndrome,” The American Journal of Psychiatry, vol. 142, no. 10, pp. 1137–1145, 1985. View at Google Scholar · View at Scopus
  17. R. J. Gurrera, S. N. Caroff, A. Cohen et al., “An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method,” Journal of Clinical Psychiatry, vol. 72, no. 9, pp. 1222–1228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Shalev and H. Munitz, “The neuroleptic malignant syndrome: agent and host interaction,” Acta Psychiatrica Scandinavica, vol. 73, no. 4, pp. 337–347, 1986. View at Google Scholar · View at Scopus
  19. D. Sierra-Biddle, A. Herran, S. Diez-Aja et al., “Neuroleptic malignant syndrome and olanzapine,” Journal of Clinical Psychopharmacology, vol. 20, no. 6, pp. 704–705, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. V. R. Velamoor, R. M. G. Norman, S. N. Caroff, S. C. Mann, K. A. Sullivan, and R. E. Antelo, “Progression of symptoms in neuroleptic malignant syndrome,” Journal of Nervous and Mental Disease, vol. 182, no. 3, pp. 168–173, 1994. View at Google Scholar · View at Scopus
  21. H. G. Pope Jr., H. G. Aizley, P. E. Keck Jr., and S. L. McElroy, “Neuroleptic malignant syndrome: long-term follow-up of 20 cases,” Journal of Clinical Psychiatry, vol. 52, no. 5, pp. 208–212, 1991. View at Google Scholar · View at Scopus
  22. D. Berardi, M. Amore, P. E. Keck Jr., M. Troia, and M. Dell'Atti, “Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study,” Biological Psychiatry, vol. 44, no. 8, pp. 748–754, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. W. S. Bond, “Detection and management of the neuroleptic malignant syndrome,” Clinical Pharmacy, vol. 3, no. 3, pp. 302–307, 1984. View at Google Scholar · View at Scopus
  24. J. M. Davis, S. N. Caroff, and S. C. Mann, “Treatment of neuroleptic malignant syndrome,” Psychiatric Annals, vol. 30, no. 5, pp. 325–331, 2000. View at Google Scholar · View at Scopus
  25. P. Sakkas, J. M. Davis, P. G. Janicak, and Z. Wang, “Drug treatment of the neuroleptic malignant syndrome,” Psychopharmacology Bulletin, vol. 27, no. 3, pp. 381–384, 1991. View at Google Scholar · View at Scopus
  26. M. R. Rosenberg and M. Green, “Neuroleptic malignant syndrome: review of response to therapy,” Archives of Internal Medicine, vol. 149, no. 9, pp. 1927–1931, 1989. View at Google Scholar · View at Scopus
  27. K. Yamagata, K. Onizawa, H. Yusa, T. Wakatsuki, T. Yanagawa, and H. Yoshida, “Risk factors for postoperative delirium in patients undergoing head and neck cancer surgery,” International Journal of Oral and Maxillofacial Surgery, vol. 34, no. 1, pp. 33–36, 2005. View at Publisher · View at Google Scholar · View at Scopus